Hvis hæmoglobinniveauet efter fire ugers behandling er steget med mindst 1 g/ dl (0, 62 mmol/ l), bør den anvendte dosis bibeholdes.
If, after 4 weeks of therapy, the haemoglobin value has increased by at least 1 g/ dl (0.62 mmol/ l), the current dose should be continued.